Sarcoma Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Sarcoma Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : August, 2020 | Pharmaceutical | PPT format

Report Digest


Global Sarcoma Drugs Market: Overview

A sarcoma, a rare form of cancer, differs from the more common carcinomas in one major way – they occur in a different type of tissue known as connective tissue. Those are essentially cells that support or connect other types of tissue in the human body. Sarcoma is highly common in muscles, bones, fats, nerves, cartilage, and blood vessels in one’s arms and legs. They can, however, also happen in other areas in the body.

The report on the global sarcoma drugs market finds that the market would rise at a healthy clip owing to emergence and acceptance of novel sarcoma drugs for treatment, a solid pipeline in the development phase, increasing allocation on research and development, and growing occurrence of soft tissue sarcomas.

Global Sarcoma Drugs Market: Drivers and Restraints

At present, chemotherapy regimens and targeted therapy are the two popular form of cure in the sarcoma drugs market. Between the two, the targeted therapy is predicted to see greater uptake in the near term because of its greater efficacy. Such treatments make use of drugs or antibodies formulated from the immune system to thwart proliferation of harmful cancer cells while leaving out the normal cells undamaged.

Other popular forms of cure in the sarcoma drugs market are surgeries in which the tumor is removed from the body or radiation in which the tumor cell is shrunk before surgery or the remaining cells killed post.

A noticeable trend in the global sarcoma drugs market is money and efforts being expended for numerous immune-oncology agents. The sarcoma drugs has also received a major boost from the approval of new chemotherapy drugs, namely Johnson & Johnson’s Yondelis and Eisai’s Halaven. They have a far greater efficacy than the earlier anthracycline-based treatment regimens.

Global Sarcoma Drugs Market: Trends and Opportunities

There are 50 different types of sarcomas known today. Those can be broadly classified into bone sarcoma (osteosarcoma) and soft tissue sarcoma. The soft tissue sarcoma currently account for almost 87.0% of all sarcoma cases. Bone sarcomas, which are considered malignant, account for just 13.0% of all cases. Hence, the soft tissue sarcomas currently present maximum opportunity in the global sarcoma drugs market.

There are almost 45 drugs in the clinical pipeline in the global sarcoma drugs market. Besides, cancer vaccines and gene therapy are also emerging as potential treatments for soft tissue cancer. Numerous monoclonal antibodies and small molecules are in active development in Phase I and II trials as well.

Global Sarcoma Drugs Market: Regional Analysis

From a geographical standpoint, the U.S. at present forms the nerve center of the global sarcoma drugs market. Presence of a clutch of key players in the region, high government allocations towards research and development for sarcoma drugs, higher per capita medical spends of people, state-of-the-art research and healthcare facilities, and most importantly more number of sarcoma cases in the region have majorly fuelled its market.

The European Union region is also a crucial sarcoma drugs market because of the greater understanding of tumor microenvironment predicted to occur in the next couple of years thereby resulting in development of new patient-specific therapies.

Global Sarcoma Drugs Market: Competitive Landscape

Some of the prominent participants in the global sarcoma drugs market that have been profiled in the report are Novartis, Amgen, Eli Lilly, Pfizer, Eisai, Johnson & Johnson, and Bayer. Besides throwing light on their products, the report also studies late-stage pipeline products of certain companies. The report observes savvy companies are embarking upon collaborations for conducting clinical trials, development, and broader product portfolios to bolster their positions in the global sarcoma drugs market.

The study presents a granular assessment and quantitative evaluation of:

  • Key growth factors and prominent trends
  • Size and share of key segments in overall market
  • Key challenges and winning imperatives
  • Factors shaping competitive landscape
  • Insights into how contours of market will change in coming years
  • Technological advances
  • New avenues and imminent investment pockets
  • Regulatory landscape shaping current and future strategies of companies

The region-wise assessment includes market dynamics in:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.

The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:

  • Which key factors will shape the competitive landscape?
  • Which trends will stimulate research and development activities in different geographies?
  • Which are the lucrative growth areas and what is the size of potential they are likely contribute to the overall market?
  • Which disruptions in market growth are likely to come with the new business models?
  • Which are some of the recent overhauls in policies that may change the course of the market significantly?
  • Which are the geographies that will form sizable sources of new streams to new and established players alike?
  • How are top players likely to realign their strategy to counter the forces of competition?
  • Which key strategies emerging players are likely to focus on to consolidate their position?
  • Which changes in end-user preferences might affect the status quo held by the leading players?
  • Which are some of the game-changing innovations influencing the projected share and revenue of the market and its segments?

Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.